The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Beam Therapeutics Inc shares valued at $11,456 were sold by Cavanagh Bethany J on Oct 01 ’25. At $24.53 per share, Cavanagh Bethany J sold 467 shares. The insider’s holdings dropped to 44,045 shares worth approximately $1.23 million following the completion of this transaction.
Also, Bellon Christine sold 373 shares, netting a total of over 9,150 in proceeds. Following the sale of shares at $24.53 each, the insider now holds 116,921 shares.
Before that, Evans John M. had sold 25,000 shares from its account. In a trade valued at $615,668, the CEO traded Beam Therapeutics Inc shares for $24.63 each. Upon closing the transaction, the insider’s holdings decreased to 25,000 shares, worth approximately $27.5 million.
As published in their initiating research note from Jefferies on October 09, 2025, Beam Therapeutics Inc [BEAM] has been a Buy and the price target has been revised to $41. Analysts at BofA Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late March. As of March 10, 2025, Scotiabank has increased its “Sector perform” rating to a “Sector outperform” for BEAM. Earlier on January 29, 2025, Cantor Fitzgerald upgraded its rating. Their new recommendation was “an Overweight” for BEAM stock which previously was a “a Neutral”.
Analyzing BEAM Stock Performance
On last trading session, Beam Therapeutics Inc [NASDAQ: BEAM] rose 3.22% to $27.87. The stock’s lowest price that day was $27.09, but it reached a high of $28.75 in the same session. During the last five days, there has been a surge of approximately 8.91%. Over the course of the year, Beam Therapeutics Inc shares have jumped approximately 19.15%. Shares of the company reached a 52-week high of $35.25 on 02/18/25 and a 52-week low of $13.52 on 04/07/25.
Support And Resistance Levels for Beam Therapeutics Inc (BEAM)
According to the 24-hour chart, there is a support level at 27.06, which, if violated, would cause prices to drop to 26.24. In the upper region, resistance lies at 28.72. The next price resistance is at 29.56. RSI (Relative Strength Index) is 73.18 on the 14-day chart, showing overbought technical sentiment.
Is Beam Therapeutics Inc subject to short interest?
Stocks of Beam Therapeutics Inc saw a sharp steep in short interest on 2025-09-15 dropping by -1.67 million shares to 25.5 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 27.17 million shares. A decline of -6.54% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.98 of the overall float, the days-to-cover ratio (short ratio) decline to 8.98.
Which companies own the most shares of Beam Therapeutics Inc (BEAM)?
In terms of Beam Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 48 in the next 12 months, up nearly 77.78% from the previous closing price of $27.0. Analysts anticipate Beam Therapeutics Inc stock to reach 55 by 2025, with the lowest price target being 41. In spite of this, 6 analysts ranked Beam Therapeutics Inc stock as Buy at the end of 2025. On November 06, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and upgraded coverage with a $39.
